Had a website for awhile Seniors4Psychedelics

Mr. Ed

Mr. Ed

Be what you is not what you what you ain’t
Location
Central NY
Had a website for a while...became too time consuming.
Used AI to gather information and write letters advocating for psychedelics, particularly within the senior realm of end-of-life, resolving the past, acceptance, socialization, psychedelic therapy. Provided information, support, videos and book file sharing.

Focus on changing the old, outdated narrative from 1960-1979s war on drugs with up to date information and scientific studies
AI helped me create a tripping companion Morning-Bridge.
morning-bridge spirit psychedelic companion .jpgIMG_0047.jpgIMG_0137.jpg28245606-AB6B-4FD4-A200-710CCE124B6C.jpg
 

The site was an attempt to educate primarily seniors of the benefits of psychedelics at the end stages of life. Psychedelics are helpful in resolving life's disappointments, and opens opportunities for socialization, inner reflection, combats depression, unites and empowers people to advocate for themselves.
Radical thinking refers to a deep and transformative way of thinking that challenges conventional beliefs and assumptions, often seeking to understand the root causes of problems, it encourages questioning established norms and exploring new perspectives to inspire meaningful change In summary, radical thinking is a tool for personal and societal transformation, encouraging individuals to rethink their understanding of reality and challenge the status quo.
 
VaughanJB said:
If I knew how to get hold of magic mushrooms, or LSD, I'd try it.

But I don't. I mean, I know how to get on the dark web, but it all feels so........... desperate.
Click to expand...
i tried LSD few times in my youthood ,not something that i took to very well .i stopped affter a few pops at ,decided i didnt like it .as for the DARK WEB just download TOR BROWSER
 
roadhogg said:
i tried LSD few times in my youthood ,not something that i took to very well .i stopped affter a few pops at ,decided i didnt like it .as for the DARK WEB just download TOR BROWSER
Click to expand...
There is more to anomy than simply using TOR browser to get on the Dark Web. If you're going buy anything you have to use bitcoin or another non-traceable source of income. Bitcoins can track where and who receives payment from your account. I haven't used these but the Dark Web and the internet have Bitcoin mixers that mix your coins with other bitcoins that cannot be traced, however, these may be against the law so basically you're screwed.
It is not unusual to run TAILs or Whonix as a separate operating system on top of your computer program to avoid tracking and privacy. A VPN also helps avoid tracking and promotes privacy if purchased anonymously. Otherwise, if you're paying for a VPN out of your bank account it can be traced back to you. I did not know this until I read the TOR Dark Net Series handbook and the Art of Invisibility by Kevin Mitnick.

As far as purchasing items on the Dark Web, I find the risk of getting caught is greater than the reward. You will not find me purchasing anything on the Dark Web no matter how enticing an item might be.
 
Mr. Ed said:
There is more to anomy than simply using TOR browser to get on the Dark Web. If you're going buy anything you have to use bitcoin or another non-traceable source of income. Bitcoins can track where and who receives payment from your account. I haven't used these but the Dark Web and the internet have Bitcoin mixers that mix your coins with other bitcoins that cannot be traced, however, these may be against the law so basically you're screwed.
It is not unusual to run TAILs or Whonix as a separate operating system on top of your computer program to avoid tracking and privacy. A VPN also helps avoid tracking and promotes privacy if purchased anonymously. Otherwise, if you're paying for a VPN out of your bank account it can be traced back to you. I did not know this until I read the TOR Dark Net Series handbook and the Art of Invisibility by Kevin Mitnick.

As far as purchasing items on the Dark Web, I find the risk of getting caught is greater than the reward. You will not find me purchasing anything on the Dark Web no matter how enticing an item might be.
Click to expand...
iv looked into purchasing from the dark web myself .i discovered that you need the bitcoin ,left it at that .as im in the UK the purchase sites were american thanks for tips on VPN and tracking i wasnt aware of the risks
 
Mr. Ed said:
Focus on changing the old, outdated narrative from 1960-1979s war on drugs with up to date information and scientific studies
Click to expand...
The narrative I heard in the 60's was that taking LSD was a great mind expanding experience that allows for spiritual awakening and enhances musical and artistic ability.

The up to date information from scientific studies I've read are these:

For individuals with a family history or genetic susceptibility to psychosis, LSD use is considered an environmental trigger that can lead to an earlier onset of a schizophrenia spectrum disorder. One study found that people visiting the emergency department for hallucinogen use had a 21 times higher risk of being diagnosed with a schizophrenia spectrum disorder within three years compared to the general population.
 
The statements I provided are based on the current body of research and regulatory actions in the field of psychedelic science.
Here are the sources and key scientific bodies supporting the information, categorized by topic:
1. Therapeutic Potential and Clinical Trials
The evidence for treating mental health conditions (PTSD, Depression, Anxiety) comes primarily from large-scale clinical trials and major research centers.
* Psilocybin for Depression (Major Depressive Disorder/MDD & Treatment-Resistant Depression/TRD):
* Source: Clinical trials sponsored by organizations like the Usona Institute and COMPASS Pathways, which have released positive Phase 2 and Phase 3 data showing significant, rapid, and durable reduction in depressive symptoms following a single psilocybin-assisted session.
* Reference Examples: Studies cataloged on ClinicalTrials.gov (e.g., NCT03866174, NCT06303739) and meta-analyses published in journals like The BMJ (e.g., Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis).
* MDMA for Post-Traumatic Stress Disorder (PTSD):
* Source: Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), which showed significant reductions in PTSD symptoms, with results lasting for months to years.
* Reference: Clinical studies (e.g., published in Nature Medicine and the Journal of Psychopharmacology) that led to the application for FDA approval.
* Major Research Centers: Institutions like Johns Hopkins Center for Psychedelic & Consciousness Research and NYU Langone Health are pioneers in this research, publishing extensive data on the efficacy of psilocybin for conditions including depression and anxiety related to end-of-life care.
2. FDA Breakthrough Therapy Designation
The FDA designation is a formal, public acknowledgment of the potential for these treatments.
* MDMA for PTSD:
* Source: U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in 2017.
* Psilocybin for Depression:
* Source: The FDA has granted Breakthrough Therapy Designation to psilocybin (and its analogs) for Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) on multiple occasions (e.g., in 2018 and 2019).
* Context: This designation is given to drugs that treat a serious condition and show preliminary clinical evidence of a substantial improvement over available therapy.
3. The Role of Supervision and Risks (Set and Setting)
The distinction between supervised medical use and unsupervised recreational use is a central theme in all modern psychedelic research.
* Safety and Controlled Setting:
* Source: Reports and review articles from the National Institute on Drug Abuse (NIDA) and peer-reviewed journals emphasize that psychedelics have a reassuring safety profile in highly controlled clinical trial settings, but carry serious risks for some patients, especially outside of medical supervision.
* Adverse Reactions and Screening:
* Source: Academic literature on psychedelic-assisted therapy stresses the necessity of careful screening for contraindications (e.g., history of psychosis/schizophrenia) and the need for trained therapists to manage psychological distress (e.g., "bad trips") and potential worsening of mood or thought disorder.
* Reference: Studies on risk assessment in psychedelic therapies (e.g., articles published by the NIH in PMC or the Cleveland Clinic Journal of Medicine) highlight that a safe environment (setting) and psychological preparation (set) are essential for mitigating acute psychiatric risks.
 
Last edited:
Paco Dennis said:
The statements I provided are based on the current body of research and regulatory actions in the field of psychedelic science.
Here are the sources and key scientific bodies supporting the information, categorized by topic:
1. Therapeutic Potential and Clinical Trials
The evidence for treating mental health conditions (PTSD, Depression, Anxiety) comes primarily from large-scale clinical trials and major research centers.
* Psilocybin for Depression (Major Depressive Disorder/MDD & Treatment-Resistant Depression/TRD):
* Source: Clinical trials sponsored by organizations like the Usona Institute and COMPASS Pathways, which have released positive Phase 2 and Phase 3 data showing significant, rapid, and durable reduction in depressive symptoms following a single psilocybin-assisted session.
* Reference Examples: Studies cataloged on ClinicalTrials.gov (e.g., NCT03866174, NCT06303739) and meta-analyses published in journals like The BMJ (e.g., Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis).
* MDMA for Post-Traumatic Stress Disorder (PTSD):
* Source: Phase 3 trials conducted by the Multidisciplinary Association for Psychedelic Studies (MAPS), which showed significant reductions in PTSD symptoms, with results lasting for months to years.
* Reference: Clinical studies (e.g., published in Nature Medicine and the Journal of Psychopharmacology) that led to the application for FDA approval.
* Major Research Centers: Institutions like Johns Hopkins Center for Psychedelic & Consciousness Research and NYU Langone Health are pioneers in this research, publishing extensive data on the efficacy of psilocybin for conditions including depression and anxiety related to end-of-life care.
2. FDA Breakthrough Therapy Designation
The FDA designation is a formal, public acknowledgment of the potential for these treatments.
* MDMA for PTSD:
* Source: U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in 2017.
* Psilocybin for Depression:
* Source: The FDA has granted Breakthrough Therapy Designation to psilocybin (and its analogs) for Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD) on multiple occasions (e.g., in 2018 and 2019).
* Context: This designation is given to drugs that treat a serious condition and show preliminary clinical evidence of a substantial improvement over available therapy.
3. The Role of Supervision and Risks (Set and Setting)
The distinction between supervised medical use and unsupervised recreational use is a central theme in all modern psychedelic research.
* Safety and Controlled Setting:
* Source: Reports and review articles from the National Institute on Drug Abuse (NIDA) and peer-reviewed journals emphasize that psychedelics have a reassuring safety profile in highly controlled clinical trial settings, but carry serious risks for some patients, especially outside of medical supervision.
* Adverse Reactions and Screening:
* Source: Academic literature on psychedelic-assisted therapy stresses the necessity of careful screening for contraindications (e.g., history of psychosis/schizophrenia) and the need for trained therapists to manage psychological distress (e.g., "bad trips") and potential worsening of mood or thought disorder.
* Reference: Studies on risk assessment in psychedelic therapies (e.g., articles published by the NIH in PMC or the Cleveland Clinic Journal of Medicine) highlight that a safe environment (setting) and psychological preparation (set) are essential for mitigating acute psychiatric risks.
Would you like me to find the full text or abstracts for any of the specific papers or FDA documents mentioned?
Click to expand...
WOW
 
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experiments on patients with schizophrenia have been conducted up to date, except for some old semi-anecdotal studies mainly performed in the time-span ‘50s-‘60s. Notably, these studies reported interesting findings, particularly on the improvement of negative symptoms and social cognition. With no doubts the lack of modern clinical studies is due to the psychomimetic properties of psychedelics, a noteworthy downside that could worsen positive symptoms. However, a rapidly increasing body of evidence has suggested that the mechanisms of action of such compounds partially overlaps with the pathogenic underpinnings of schizophrenia but in an opposite way.

These findings suggest that, despite being a controversial issue, the use of psychedelics in the treatment of schizophrenia would be based on a strong biological rationale. Therefore, the aim of our perspective paper is to provide a background on the old experiments with psychedelics performed on patients with schizophrenia, interpreting them in the light of recent molecular findings on their ability to induce neuroplasticity and modulate connectivity, the immune and TAARs systems, neurotransmitters, and neurotropic factors.

No systematic approach was adopted in reviewing the evidence given the difficulty to retrieve and interpret old findings. Interestingly, we identified a therapeutic potential of psychedelics in schizophrenia adopting a critical point of view, particularly on negative symptoms and social cognition, and we summarized all the relevant findings. We also identified an eligible subpopulation of chronic patients predominantly burdened by negative symptoms, outlining possible therapeutic strategies which encompass very low doses of psychedelics (microdosing), carefully considering safety and feasibility, to pave the way to future clinical trials.
 
Search Assist

Research indicates that individuals with schizophrenia are generally excluded from psychedelic-assisted therapy due to concerns about worsening psychosis. However, recent studies suggest that the risk of psychedelic-induced psychosis in those with schizophrenia may not be as high as previously thought, although more high-quality research is needed to fully understand the relationship. Nature ices.on.ca

Overview of LSD and Schizophrenia​

LSD (lysergic acid diethylamide) is a powerful hallucinogenic drug that has been studied for its effects on mental health, including its potential relationship with schizophrenia. Research indicates that individuals with schizophrenia may be at higher risk when using psychedelics like LSD.

Scientific Findings​

Incidence of Psychosis​

  • Psychedelic-Induced Psychosis: A systematic review found that the incidence of psychedelic-induced psychosis is low in the general population, at about 0.002% in population studies and 0.6% in randomized-controlled trials (RCTs).
  • Individuals with Schizophrenia: In uncontrolled trials involving individuals with schizophrenia, the incidence of developing long-lasting psychotic symptoms was significantly higher, at 3.8%.

Risk Factors​

  • Emergency Department Visits: A study indicated that individuals who visit emergency departments due to hallucinogen use have a 21-fold increased risk of developing schizophrenia compared to the general population. Even after accounting for other mental health issues, the risk remains elevated at 3.5 times.

Therapeutic Potential and Cautions​

Modified Compounds​

  • New Developments: Researchers are exploring modified versions of LSD, such as a compound called JRT, which aims to retain therapeutic benefits while minimizing hallucinogenic effects. This could potentially make it safer for individuals with schizophrenia.

Need for Caution​

  • Exclusion from Therapy: Due to the risks of exacerbating psychosis, individuals with schizophrenia are typically excluded from psychedelic-assisted therapy trials. More high-quality research is needed to understand the safety and efficacy of psychedelics in this population.

Conclusion​

While LSD shows promise for treating various mental health conditions, its use in individuals with schizophrenia poses significant risks. Ongoing research is crucial to clarify these relationships and explore safer alternatives.
Wikipedia Nature

I disagree based on hearsay and speculation. Micro-dosing LSD may eliminate the threat of psychosis in people who have a history of psychosis. There is no hard evidence that shows LSD responsible psychosis associated with schizophrenia.

Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and its therapeutic potential for psychiatry.
 
Summary: A new LSD-derived compound called JRT shows promise for treating schizophrenia and other brain disorders without inducing hallucinations. Developed by researchers who altered just two atoms in LSD’s structure, JRT maintains the psychedelic’s neuroplastic effects while avoiding its psychosis-linked risks.

In mouse models, JRT enhanced synaptic growth, boosted antidepressant effects, and improved cognitive flexibility—key challenges in schizophrenia treatment. These findings support the idea that psychedelics can be safely reengineered to unlock brain repair without perceptual side effects.
 
Trade said:
I'm just the opposite. Never tried it when I was young but I wouldn't mind trying it now. At this age I don't have that much life left to ruin if things go south.
Click to expand...
Maybe I should explain it a bit more.
When I was younger I could count on others to get clean drugs. If I wanted x drugs I would get x drugs. Never did I get xyz drug. I knew what I was getting. I could trust my friends

Plus I have a lot of metal disorders including the start of dementia. I could vision myself panicking.
 
Brain and Behavior Research Institute:

Antipsychotic drugs block the D2 dopamine receptor in nerve cells and are often highly effective in reducing the positive symptoms of the illness including hallucinations and delusions. Thought- and reality-distorting symptoms like these are among the principal effects of hallucinogens like LSD, making them especially dangerous for those with schizophrenia, psychosis, or a family history of either.
Click to expand...
 

You must log in or register to reply here.

Back
Top